Kara Meinke Baehr, MD
Endocrinology, Diabetes & Metabolism · Lincoln, NENPI 1679692750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NE, where the typical reported total is $1,422.
Across 81 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$291
- Tandem Diabetes Care, Inc.$207
- Medtronic$156
- Abbott$124
- Dexcom, Inc.$89
- Insulet Corporation$63
- plus $491 from 16 others
What the payments were for
- Food & beverage$1,422100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $291 |
| Tandem Diabetes Care, Inc. | 14 | $207 |
| Medtronic(2 entities) | 8 | $156 |
| Abbott | 6 | $124 |
| Dexcom, Inc. | 6 | $89 |
| Insulet Corporation | 3 | $63 |
| Amgen | 3 | $57 |
| Boehringer Ingelheim | 3 | $52 |
| Ascendis Pharma Endocrinology Inc | 3 | $46 |
| Ascensia Diabetes Care US Inc. | 2 | $44 |
| Lilly USA, LLC | 3 | $41 |
| AstraZeneca | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $31 |
| AbbVie | 1 | $24 |
| Amphastar Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $23 |
| Valeritas, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Bayer | 1 | $13 |
| Tolmar, Inc. | 1 | $13 |
How this compares
$1,422 in reported general payments places this provider in the 50th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $187,924 |
| JardianceEmpagliflozin | 220 | $180,400 |
| MounjaroTirzepatide | 131 | $135,691 |
| TrulicityDulaglutide | 110 | $129,451 |
| Tresiba Flextouch U-100Insulin Degludec | 182 | $113,584 |
| Tresiba Flextouch U-200Insulin Degludec | 101 | $109,715 |
| Humulin R U-500Insulin Regular, Human | 49 | $70,327 |
| FarxigaDapagliflozin Propanediol | 89 | $62,082 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $49,781 |
| Humalog Kwikpen U-100Insulin Lispro | 146 | $49,170 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $43,843 |
| Novolog FlexpenInsulin Aspart | 157 | $42,308 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $38,537 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 235 | $31,972 |
| Xigduo XrDapaglifloz Propaned/Metformin | 33 | $22,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $41 | $275,989318 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $52 | $232,778293 claims |
| Novo NordiskOzempic, Novolog | $291 | $198,460211 claims |
| AstraZenecaFarxiga | $36 | $62,08289 claims |
| AbbVieSynthroid | $24 | $13,571180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
Other endocrinology, diabetes & metabolism in Lincoln
- Shannon WakeleyLincoln$78K
- Madeline Jones RyanLincoln$4K
- Prathima JastiLincoln$1K
- Jalal NafachLincoln$110
- Marium IlahiOmaha$170K
- Cyrus DesouzaOmaha$86K
- Timothy WahlOmaha$41K
- Leslie EilandOmaha$17K
- Anupam KotwalOmaha$17K
- John GallagherOmaha$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.